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Abstract
Recurrent angina (RA) has an important inﬂuence on health status of patients after percutaneous coronary intervention (PCI). This
study aimed to retrospectively investigate the effect of multiple clinical factors on both short-term and long-term development of RA.
A total of 398 ST-segment elevation myocardial infarction (STEMI) patients were studied for up to 12 months. The primary clinical
outcome, RA, was assessed at 1-month and 12-month. In multivariate analyses, the effect of clinical factors, including baseline
demographics, medical history, infarction-related arteries, procedural characteristics of PCI, and the use of medicines, was
investigated in patients with and without RA.
The Logistic regression analysis showed that the patients with treatment through radial approach PCI (odds ratio [OR]: 0.42, 95%
conﬁdence interval [CI]: 0.18–0.96, P<0.05) were less likely to have RA during 1-month assessment. During 12 months after PCI,
male patients (OR: 0.53, 95%CI: 0.29–0.96, P<0.05), and/or those treated with radial approach PCI (OR: 0.45, 95%CI: 0.21–0.97,
P<0.05) were less likely to have RA, whereas the patients with infarction related artery (IRA) in left anterior descending (LAD) (OR:
2.41, 95% CI: 1.20–4.84, P<0.01) were more likely to have RA at follow-up. The Cox regression analysis further revealed that the
patients with infarction of the LAD artery (hazard ratio [HR]: 2.08, 95% CI: 1.10–3.92, P<0.05), but not with treatment through radial
artery during PCI (HR: 0.42, 95% CI: 0.18–0.96, P<0.05) had higher potential of development of RA during 12 months after PCI.
We studied the effects of multiple clinical factors on the development of RA after PCI. Our ﬁndings suggest that patients with
infarction of the LAD artery, and/or treatment not through radial artery during PCI were associated with higher risk of RA and may
require close follow-up.
Abbreviations: ACEI = angiotensin converting enzyme inhibitors, ACS = acute coronary syndrome, AMI = acute myocardial
infarction, ARB = angiotensin receptor blockers, CCB = calcium channel blockers, CHD = coronary heart disease, CI = conﬁdence
interval, DBP = diastolic blood pressure, DM = diabetes mellitus, HC = hypercholesterolemia, HR = hazard ratio, HTG =
hypertriglyceridemia, IABP = intra-aortic balloon pump, IRA = infarction related artery, LAD = left anterior descending, LCX = left
circumﬂex, OR = odds ratio, PCI = percutaneous coronary intervention, RA = recurrent angina, RCA = right coronary artery, SBP =
systolic blood pressure,, SD = standard deviation, STEMI = ST-segment elevation myocardial infarction, TP = temporary pacing.
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11. Introduction
Despite advances in therapeutic techniques, acute coronary
syndrome (ACS) remains amajor cause ofmorbidity andmortality
worldwide.[1,2] Multiple risk factors for this disease have been
identiﬁed,[3] including hypertension, hypercholesterolemia, obesi-
ty, diabetes, and genetic factors, for example, the polymorphisms
of G protein-coupled receptor kinases (GRKs) gene,[4]calcium/
calmodulin-dependent kinase IV gene (CaMK4),[5] and platelet
antigen 2 (PlA2) gene.[6,7] Percutaneous coronary intervention
(PCI), one of the main treatment approaches for ACS, has
effectively reduced both short-term and long-term mortality
in patients with ST-segment elevation myocardial infarction
(STEMI).[8]
Previous studies have investigated the effect of various clinical
factors, such as sex,[9,10] blood pressure,[11] medical history,[12,13]
infarction-related artery (IRA),[14–16] medications,[17] and PCI
procedural characteristics[18,19] on the mortality of ACS patients.
Such studies, however, have primarily focused on mortality and
not on health outcomes of patients after PCI.
Recurrent angina (RA), deﬁned as recurrence or persistence of
chest pain or discomfort,[20] is a challenging condition and is one
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STEMI patients.[20,21] RA can be caused by structural factors
(including in-stent thrombosis, restenosis, incomplete revascu-
larization, or atherosclerotic disease progression),[22] or by
functional factors (e.g., microvascular dysfunction, epicardial
coronary spasm, or vasoconstriction at the stent edge).[23] It has
been reported that up to one-third of patients treated with PCI
might present with RA without clear obstructive structural
lesions.[23]2. Hypothesis
Our hypothesis is that the occurrence of RA is the result of
multiple clinical factors. Therefore, this study aimed to
retrospectively investigate both short-term and long-term effects
of multiple clinical factors on the development of RA and attempt
to identify predictors for increased likelihood of RA in STEMI
patients after PCI, particularly in Northwest of China.3. Methods
3.1. Patient population
A total of 416 STEMI patients who had undergone PCI at the
Heart Center of the First Afﬁliated Hospital of Lanzhou
University in China from 2009 to 2012 were enrolled in this
study. The inclusion criteria were patients who had been
diagnosed with STEMI following the ACC/AHA guidelines[24];
all patients who had undergone coronary angiography and
successful reperfusion therapy to the IRA using the PCI
procedure.
Eighteen patients were excluded because they had a history of
any of the following: treatment with thrombolytic therapy or
coronary artery bypass graft; cerebral hemorrhage less than 1 year
or cerebral infarction <6 months; severe liver or kidney
dysfunction; tumor patients; coagulopathy; contraindication of
anti-platelet drug; andanypatientswhohad the inadequate clinical
notes orwere unreachable via telephone follow-up. Therefore, 398
patients met the inclusion criteria and were analyzed in this study.
The institutional review board at the First Afﬁliated Hospital of
Lanzhou University granted a waiver of written informed consent
and provided authorization for this study.3.2. Treatment procedure
Each patient was given a dose of 300-mg aspirin and 300-mg
clopidogrel before the PCI procedure. The PCI approach was
performed through either radial or femoral artery. In addition,
patients were implanted with the temporary pacing electrode if they
had severe sinus bradycardia or II∼III° atrioventricular block before
operation. If cardiogenic shockorhemodynamic instability happened
during operation, they were treated with intra-aortic balloon pump.
Antiplatelet, antithrombin, statin, nitrates, ACEI/ARB, and other
necessary medicine therapy were given to patients based on the
ACC/AHA Guidelines during the treatment period.[24] After PCI,
patients were given life-long aspirin 100mg/day and clopidogrel 75
mg/day for at least 12 months.
3.3. Study clinical outcome
RA was the primary clinical outcome in this study. It was deﬁned
as angina recurrence or persistence, either stable or unstable after
PCI,[20] without documented noncardiac causes of chest pain,
such as gastrointestinal, pulmonary, musculoskeletal, or herpes2zoster. Stable angina was deﬁned as pain precipitated by exertion
and relieved by rest and/or sublingual nitroglycerin, with no
change in pattern or severity in the previous 6 weeks. Unstable
angina was deﬁned as either pain that presented at rest, or
exertional pain of at least Canadian Cardiovascular Society class
III that began or increased in severity at least I Canadian
Cardiovascular Society class in the previous 2 months.[21]
Patients who reported chest pain or discomfort were classiﬁed
as having angina according to the validated Seattle Angina
Questionnaire, which also included the severity, frequency, and
stability subscales of the symptoms.[25]
The secondary clinical outcome in this study was all-cause
death, allowing us to investigate factors associated with the
incidence of death during the study period.3.4. Data collection, management, and patient follow-up
Patients included in the study were followed for 12 months after
PCI to determine the reoccurrence of angina or if patients died
during the study period from any cause. In-person or telephone
interviews were conducted to determine RA. Among these 398
STEMI patients, 212 patients were followed up by face-to-face
and 186 patients were followed up via telephone. During the
interview, patients were asked if they had chest pain or
discomfort (anginal symptoms) after PCI procedure, and to
describe the severity and frequency of the symptoms, as relevant.
Thus, patients were placed into 2 categories for analysis by
presentation of RA or not, for both 1-month and 12-month
follow-up assessment.
3.5. Statistical analysis
Continuous variables were presented as median (25th, 75th
percentiles) or mean value ± SD, and were compared by unpaired
t test or Mann–Whitney U test. For categorical variables,
frequencies and the corresponding percentages were given, and
were compared by x2 test with continuity correction or Fisher
exact test.
Logistic regression was ﬁrst performed to test the risk factors.
The following covariates were analyzed: demographic character-
istics, medical history (coronary heart disease family history,
diabetes mellitus, hypertriglyceridemia, hypercholesterolemia
and smoking history), IRA, use of medication, and PCI
procedural characteristics. Univariate correlates of RA with a
value of P0.1 were included in multivariate logistic regression
analysis to further identify the potential risk factors for
developing RA. The results were displayed as adjusted odds
ratios (ORs) with 95% conﬁdence intervals (CIs).
To further check our results, cox regression analysis was also
performed. In the Cox regression model, the covariates were
selected based upon univariate signiﬁcance of P value 0.1. The
results were reported as adjusted hazard ratios (HRs) with 95%
CIs. In addition, a survival curve was also provided.
All analyses were performed using SPSS software version 22
(IBM Corp., Armonk, NY), and a P value of <0.05 was
considered statistically signiﬁcant.
4. Results
4.1. Baseline demographics
A total of 398 patients with STEMI and PCI met the inclusion
criteria and were included in the study analyses. Table 1 describes
the baseline demographics of the reserved patients. The median
Table 1
Basic demographics of the reserved 398 STEMI patients.
Variables Value 95% CI
Sex 335 (M); 63 (F) —
Age, y 59 (52–67) 58–60
SBP, mmHg 120 (106–136) 119–124
DBP, mmHg 75 (67–84) 74–77
Note: Data are presented as median (25th–75th percentiles). CI= conﬁdence interval, DBP=diastolic
blood pressure, SBP= systolic blood pressure.
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Median systolic and diastolic blood pressures were 120mmHg
and 75mmHg, respectively.4.2. Comparison of baseline demographics and clinical
characteristics
Table 2 shows the different baseline demographics and clinical
characteristics between the patients with and without RA at
1-month and 12-month assessments, respectively. Among theTable 2
Comparison results of the baseline demographics and clinical charac
1-month and 12-month follow-up.
Factors
1-month follow-up
With RA Without RA
Demographic
Patients number 62 336
Age, year 60 (53–68) 59 (52–67)
Male sex 47 (76) 288 (86)
SBP, mmHg 119 (100–137) 120 (106–136)
DBP, mmHg 79 (66–88) 75 (67–84)
Medical history
CHD family history 3 (5) 15 (4)
Hypertension 27 (44) 142 (42)
DM 6 (10) 48 (14)
HTG 18 (29) 87 (26)
HC 7 (11) 27 (8)
Smoking history 37 (60) 187 (56)
IRA
LAD 55 (89) 250 (74)
LCX 27 (44) 144 (43)
RCA 29 (47) 198 (59)
Number of IRA
Only one vessel 27 (44) 155 (46)
Two vessels 21 (34) 107 (32)
Three vessels 14 (23) 74 (22)
Use of medication
b-blocker 43 (69) 194 (58)
Statin 58 (94) 332 (99)
ACEI 32 (52) 166 (49)
ARB 24 (39) 81 (24)
CCB 7 (11) 22 (7)
Nitrate 35 (56) 199 (59)
Procedural characteristics
Radial approach 52 (84) 311 (93)
IABP 2 (3) 5 (1)
TP 6 (10) 46 (14)
Number of stent 1 (1–2) 2 (1–2)
Note: Data are presented as number (%) or median (25th–75th percentiles).
ACEI=angiotensin converting enzyme inhibitors, ARB= angiotensin receptor blockers, CCB= calcium cha
HC=hypercholesterolemia, HTG=hypertriglyceridemia, IABP= intra-aortic balloon pump, IRA= infarction-
coronary artery, SBP= systolic blood pressure, TP= temporary pacing.
3total of 398 patients, 62 had RA at 1-month follow-up and
98 had RA at 12-month follow-up, which included all of the
62 patients who had RA at 1 month.
Sex was the only statistically signiﬁcant demographic charac-
teristic between the 2 groups, and males were less likely to
experience RA (at 1-month assessment, 76% vs. 86%, P<0.05;
at 12-month assessment, 77% vs. 87%, P<0.05).
There were multiple statistically signiﬁcant clinical character-
istics. At 1-month assessment, patients were more likely to
experience RA if they had higher IRA of left anterior descending
(LAD) (89% vs. 74%, P<0.05); lower percentage of using statin
(94% vs. 99%, P<0.05), higher percentage of using ARB (39%
vs. 24%, P<0.05); and lower percentage of radial approach in
PCI procedure (84% vs. 93%, P<0.05).
At 12-month assessment, RA was observed more commonly in
patientswho had IRA inLAD (88%vs. 73%,P<0.01); less IRA in
right coronary artery (RCA) (46% vs. 61%, P<0.05); a lower
percentageof radial approach inPCIprocedure (86%vs. 93%,P<
0.05); and less number of stent (1 vs. 2, P<0.05). The signiﬁcantly
statistical difference observed with use of statin and ARB at 1
monthwas no longer evident following the assessent at 12months.teristics between the patients with and without RA, separated by
12-month follow-up
P With RA Without RA P
— 98 300 —
0.6 59 (51–68) 59 (53–67) 0.8
<0.05 75 (77) 260 (87) <0.05
0.9 120 (108–136) 120 (106–137) 0.9
0.3 76 (68–86) 75 (67–84) 0.3
0.8 5 (5) 13 (4) 0.8
0.9 41 (42) 128 (43) 0.9
0.3 13 (13) 41 (14) 0.9
0.6 25 (26) 80 (27) 0.8
0.4 12 (12) 22 (7) 0.1
0.6 57 (58) 167 (56) 0.7
<0.05 86 (88) 219 (73) <0.01
0.9 40 (41) 131 (44) 0.6
0.1 45 (46) 182 (61) <0.05
0.9 47 (48) 135 (45) 0.8
29 (30) 99 (33)
22 (22) 66 (22)
0.1 62 (63) 175 (58) 0.4
<0.05 296 (99) 94 (96) 0.1
0.7 53 (54) 145 (48) 0.3
<0.05 33 (34) 72 (24) 0.1
0.2 10 (10) 19 (6) 0.2
0.7 55 (56) 179 (60) 0.5
<0.05 84 (86) 279 (93) <0.05
0.3 3 (3) 4 (1) 0.4
0.4 11 (11) 41 (14) 0.5
0.1 1 (1–2) 2 (1–2) <0.05
nnel blockers, CHD= coronary heart disease, DBP=diastolic blood pressure, DM=diabetes mellitus,
related artery, LAD= left anterior descending, LCX= left circumﬂex, RA= recurrent angina, RCA= right
Table 3
Effects of all potential factors on the development of recurrent angina from the Logistic REGRESSION analysis.
1-month follow-up 12-month follow-up
Univariate Multivariate Univariate Multivariate
Factors OR 95% CI P OR 95% CI P OR 95% CI P OR 95% CI P
Demographics
Age 1.01 0.98–1.04 0.58 1.00 0.97–1.02 0.76
Male sex 0.52 0.27–1.01 <0.05
∗
0.57 0.29–1.14 0.11 0.50 0.28–0.89 <0.05
∗
0.53 0.29–0.96 <0.05
SBP 1.00 0.99–1.01 0.83 1.00 0.99–1.01 0.98
DBP 1.01 0.99–1.03 0.32 1.01 0.99–1.03 0.32
Medical history
CHD family history 1.09 0.31–3.88 0.90 1.19 0.41–3.42 0.75
Hypertension 1.05 0.61–1.82 0.85 0.97 0.61–1.53 0.89
DM 0.64 0.26–1.57 0.33 0.97 0.50–1.89 0.92
HTG 1.17 0.64–2.13 0.61 0.94 0.56–1.59 0.82
HC 1.46 0.61–3.51 0.40 1.76 0.84–3.71 0.14
Smoking history 1.18 0.68–2.05 0.56 1.11 0.70–1.76 0.67
IRA
LAD 2.70 1.19–6.16 <0.05
∗
2.32 0.96–5.62 0.06 2.65 1.38–5.11 <0.01
∗
2.41 1.20–4.84 <0.01
LCX 1.03 0.60–1.78 0.92 0.89 0.56–1.41 0.62
RCA 0.61 0.36–1.06 0.08
∗
0.75 0.42–1.36 0.34 0.55 0.35–0.87 <0.01
∗
0.72 0.43–1.21 0.22
Number of IRA
Single
Double 1.13 0.61–2.10 0.71 0.84 0.50–1.43 0.52
Triple 1.09 0.54–2.19 0.82 0.96 0.53–1.72 0.88
Use of medication
b-blocker 1.66 0.93–2.96 0.09
∗
1.61 0.87–2.98 0.13 1.23 0.77–1.97 0.39
Statin 0.18 0.04–0.72 <0.05
∗
0.23 0.05–1.08 0.06 0.32 0.08–1.30 0.11
ACEI 1.09 0.64–1.88 0.75 1.26 0.80–1.99 0.32
ARB 1.99 1.13–3.51 <0.05
∗
1.79 0.98–3.28 0.06 1.61 0.98–2.64 0.06
∗
1.61 0.96–2.69 0.07
CCB 1.82 0.74–4.46 0.19 1.68 0.75–3.75 0.21
Nitrate 0.89 0.52–1.54 0.68 0.87 0.55–1.37 0.54
Procedural characteristics
Radial approach 0.42 0.19–0.92 <0.05
∗
0.42 0.18–0.96 <0.05 0.45 0.22–0.93 <0.05
∗
0.45 0.21–0.97 <0.05
IABP 2.21 0.42–11.64 0.35 2.34 0.51–10.63 0.27
TP 0.68 0.28–1.66 0.39 0.80 0.39–1.62 0.53
Number of stent 0.85 0.63–1.16 0.30 0.80 0.61–1.03 0.08
∗
0.83 0.63–1.11 0.21
ACEI=angiotensin converting enzyme inhibitors, ARB= angiotensin receptor blockers, CCB= calcium channel blockers, CHD=coronary heart disease, CI= conﬁdence interval, DBP=diastolic blood pressure,
DM=diabetes mellitus, HC=hypercholesterolemia, HTG=hypertriglyceridemia, IABP= intra-aortic balloon pump, IRA= infarction-related artery, LAD= left anterior descending, LCX= left circumﬂex, OR= odds
ratio, RCA= right coronary artery, SBP= systolic blood pressure, TP= temporary pacing. Data are presented as n (%) or median (25th–75th percentile).
∗
Means the univariate features (P0.1) included in multivariate regression analysis.
Zhang et al. Medicine (2016) 95:41 MedicineNeither medical history nor the number of diseased vessels
showed any statistical signiﬁcant differences in the occurrence of
RA (all P≥0.05) at 1-month or 12-month assessment.4.3. Risk factors for the development of RA from logistic
regression analysis
Table 3 summarizes the effect of all potential factors on the
development of RA using logistic regression analysis. The key risk
factors at the 2 independent time points (1-month and 12-month
follow-up) have been identiﬁed from the univariate and
multivariate regression analysis.
At 1-month assessment, univariate analysis identiﬁed sec,
LAD, RCA, b-Blocker, statin, ARB, and radial approach as the
potential impact factors (P0.1) for the development of RA.
However, multivariable regression model only revealed that
radial approach (OR: 0.42, 95% CI: 0.18–0.96, P<0.05)
decreased the probability of RA.
At 12-month assessment, univariate analysis identiﬁed sex,
LAD, RCA, ARB, radial approach, and number of stent as the
potential impact fators (P0.1) for the development of RA.
Meanwhile, multivariable regression model revealed that the IRA4in LAD increased while male patients and radial approach
decreased the probability of RA independent from confounding
factors (OR: 2.41, 95% CI: 1.20–4.84, P<0.01 for LAD; OR:
0.53, 95% CI: 0.29–0.96, P<0.05 for male sex; OR: 0.45, 95%
CI: 0.21–0.97, P<0.05 for radial approach).4.4. Risk factors for the development of RA from Cox
regression
Table 4 summarizes the effects of potential factors on the
development of RA using Cox regression analysis. The key risk
factors have been identiﬁed. At 12-month assessment, univariate
analysis identiﬁed sex, LAD, RCA, statin, ARB, and radial
approach as the potential impact factors (P0.1) for the
development of RA. However, multivariable regression model
only revealed that LAD (HR: 2.08, 95%CI: 1.10–3.92, P<0.05)
and radial approach (HR: 0.42, 95% CI: 0.18–0.96, P<0.05)
were statistically signiﬁcant.
Figure 1 shows the cumulative rate curve of RA for the 5
statistical time points (1, 3, 6, 9, and 12months after PCI) and the
cumulative rates of RA were 14.1%, 18.9%, 20.7%, 23.0%, and
23.2%, respectively.
Table 4
Effects of all potential factors on the development of recurrent angina from the Cox regression analysis (12-month follow-up).
Univariate Multivariate
Factors HR 95% CI P HR 95% CI P
Demographics
Age 1.00 0.98–1.02 0.81
Male sex 0.59 0.37–0.94 <0.05
∗
0.63 0.39–1.01 0.06
SBP 1.11 0.68–1.84 0.67
DBP 0.90 0.53–1.51 0.68
Medical history
CHD family history 1.16 0.47–2.84 0.75
Hypertension 0.97 0.65–1.46 0.90
DM 0.96 0.53–1.72 0.96
HTG 0.96 0.61–1.51 0.86
HC 1.54 0.84–2.83 0.16
Smoking history 1.09 0.73–1.63 0.67
IRA
LAD 2.31 1.26–4.22 <0.01
∗
2.08 1.10–3.92 <0.05
LCX 0.91 0.61–1.36 0.65
RCA 0.62 0.42–0.92 <0.05
∗
0.76 0.49–1.18 0.23
Number of IRA
Single
Double 0.88 0.55–1.39 0.58
Triple 0.97 0.58–1.61 0.91
Use of medication
b-blocker 1.20 0.79–1.81 0.39
Statin 0.41 0.15–1.12 0.08
∗
0.63 0.22–1.80 0.39
ACEI 1.20 0.81–1.79 0.36
ARB 1.49 0.98–2.26 0.06
∗
1.42 0.92–2.19 0.12
CCB 1.51 0.78–2.90 0.22
Nitrate 0.89 0.60–1.32 0.56
Procedural characteristics
Radial approach 0.54 0.30–0.94 <0.05
∗
0.42 0.18–0.96 <0.05
IABP 1.89 0.60–5.96 0.28
TP 0.68 0.44–1.54 0.55
Number of stent 0.82 0.65–1.04 0.10
∗
0.87 0.68–1.12 0.29
ACEI=angiotensin converting enzyme inhibitors, ARB= angiotensin receptor blockers, CCB= calcium channel blockers, CI= conﬁdence interval, CHD=coronary heart disease, DBP=diastolic blood pressure,
DM=diabetes mellitus, HC=hypercholesterolemia, HR=hazard ratio, HTG=hypertriglyceridemia, IABP= intra-aortic balloon pump, IRA= infarction-related artery, LAD= left anterior descending, LCX= left
circumﬂex, RCA= right coronary artery; SBP= systolic blood pressure, TP= temporary pacing.
∗
Means the univariate features (P0.1) included in multivariate regression analysis.
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Table 5 lists the risk factors for the incidence of death for both
two follow-up periods: 5 patients died in 1-month follow-up
(1.3% in all patients) and 9 patients died in 12-month follow-up
(2.3% in all patients).Figure 1. Cumulative rate curve of recurrent angina (RA) at the 5 statistical time
points: 1, 3, 6, 9, and 12 months after percutaneous coronary intervention
(PCI).
5At 1-month assessment, among the 5 death cases, 4 were male
(80%). Four of them had an IRA of LAD and also had an IRA of
RCA.Moreover, 2 dead patients used b-blocker and 2 used ARB.
At 12-month assessment, among the 9 dead cases, 6 were male
(66.7%). Eight dead patients had an IRA of LAD and 7 had an
IRA of RCA. Moreover, 4 dead patients used b-blocker and 3
used ARB. Most importantly, no matter in 1-month follow-up or
12-month follow-up, all of dead patients had radial approach
when performed PCI procedure, as well as were given statin
during the whole treatment.5. Discussion
7835968976Management of RA after PCI among STEMI
patients remains a clinical challenge. This study retrospectively
investigated both short-term (1 month) and long-term
(12-month) effects of multiple clinical factors, including
baseline demographics, medical history, infarction-related artery,
use of medication and procedural characteristics of PCI on the
development of RA after PCI for 398 STEMI patients.
We found that female STEMI patients were more likely to
experience RA. Some previous researches that studied cronary
diease and/or acute myocardial infarction (AMI) have also shown
that women had a higher short-term[20,26,27] and long-term[28]
[28]
Table 5
Risk factors for the incidence of death.
Factors Number of total patients with the factor
1-month follow-up 12-month follow-up
Number of dead patients % in dead patients Number of dead patients % in dead patients
Male sex 335 4 80 6 66.7
LAD 305 4 80 8 88.9
RCA 227 4 80 7 77.8
b-blocker 237 2 40 4 44.4
ARB 105 2 40 3 33.3
Statin 390 5 100 9 100
Radial approach 363 5 100 9 100
ARB= angiotensin receptor blockers, LAD= left anterior descending, RCA= right coronary artery.
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association is not statistically signiﬁcant after we controlled for
clinical factors such as medical history, IRA, medications, and
PCI procedural characteristics. In addition, we found that being
female is not associated with statistically signiﬁcant reduction in
mortality after PCI. In this study, 3 female patients died during
the 12-month follow-up period (1 before 1-month assessment
and 2 before the 12-month assessment). It is possible that our
analysis in mortality may be hampered by small sample size(only
63 females in total 398 patients) of STEMI patients from the
Northwest of China.
The previous studies have shown a link between smoking and
angina in AMI patients.[26,29] However, our study did not ﬁnd an
association between smoking and occurrence of RA, which is
consistent with some previous research.[28] In addition, although
another published study has reported that ACS patients with
diabetes had a higher rate of RA after PCI,[30] our study also did
not ﬁnd signiﬁcant association between the medical history
(diabetes, hypertension, and hypercholesterolemia) and outcome
of RA.
A potentially important ﬁnding of our study was that the LAD-
related infarcts seem to be related to RA in post-PCI patients. Our
results suggest that STEMI patients with RA after PCI had
signiﬁcantly higher percentage of IRA in LAD during both 1-
month and 12-month assessments. In the literature, many studies
have shown that LAD-related infarcts in patients treated with PCI
have worse prognosis and lower left ventricular ejection fraction
when compared with non-LAD-related infarcts.[31,32] This is
thought to be mainly because of the increased muscle mass at risk
and a lower likelihood of achieving normal myocardial perfusion
despite restored epicardial ﬂow, resulting in a large amount
of damaged myocardium.[33] However, to the best of our
knowledge, there is no study that reported that the LAD-related
infarcts were related to RA in post-PCI patients.
Santulli et al has reported that lymphocyte G protein-coupled
receptor kinase 2 (GRK2) levels, which is related to worse cardiac
function, increased quickly after STEMIand somepatients showed
reduced GRK2 levels in response to b-blocker therapy, suggesting
that it is important to give STEMIpatientsb-blocker therapy in the
early stage.[34,35] Another prospective study investigated the
predictor factors of RA in patients with ACS use of a population
data of China and they found use ofb-blockerwas an independent
predictive factor for RA.[17] Some studies have also shown the use
of statin reduced the incidence of RA after PCI in coronary artery
disease patients with normal cholesterol levels.[36,37] However,
neitherb-blocker nor statin has been identiﬁed as the risk factor for
the development ofRA in this study,whichonly focusedonSTEMI
patients with PCI. Our study has shown that this ﬁnding might be
related to observations.6Radial approach has been recommended by EAPI/ESC as
preferred access in primary PCI,[38] which allows early ambula-
tion, shorter hospital stay, more reduction in bleeding and access
site complications, and superior net clinical beneﬁt compared
with the femoral approach.[39–42] A strong association between
radial approach PCI and a reduction in adverse cardiovascular
events in patients with ACS has also been reported by some
randomized controlled studies.[18,19,43] Furthermore, a meta-
analysis of 12 randomized trials comparing radial and femoral
approach for primary PCI in STEMI patients has demonstrated
that mortality was signiﬁcantly reduced with the radial
approach.[44] However, to the best of our knowledge, there is
no study reported that the radial approach PCI was associated
with decreased RA.Our results found that a decreased percentage
of radial approach is associated with a signiﬁcant increase the
probability for developing RA in STEMI patients during both 1-
month and 12-month assessments. Future randomized trials will
be useful to conﬁrm these ﬁndings.6. Limitations
This study has several limitations. First, the study had a relatively
small number of patients from a single center; therefore, the
results may not be generalizable to other population. However,
this study focused on the STEMI patients from the northwest of
China only and provided useful insights regarding the occurrence
of RA in the targeted population. Second, this is an observational
study. It is possible that certain unobserved factors such as genetic
background,[3] precise mechanism, and pathophysiology[35] of
STEMI may also inﬂuence the likelihood of RA after controlling
most RA-associated risk factors in our model. Therefore, we
examined the robustness and sensitivity of our results by
employing different models. Overall, our results are very robust
to different model speciﬁcation. Finally, the content, extent, and
severity description of symptoms were self-reported, hence are
subjected to recall bias. Based on these limitations, future large-
scale clinical studies are needed.7. Conclusion
This retrospective study of 398 STEMI patients explored the effect
ofmultiple demographic and clinical factors on the development of
RA after PCI. Our results suggest that patients with infarction of
left anterior descending artery were associated with higher risk of
RA during the follow-up. Compared with femoral approach,
patients experienced the treatment through radial artery during
PCI are related to lower risks of RA for up to 1 year after the
procedure. Further research, with a nationally representative
sample and a prospective study design or longer-term follow-up
[19] Romagnoli E, Biondi-Zoccai G, Sciahbasi A, et al. Radial versus femoral
Zhang et al. Medicine (2016) 95:41 www.md-journal.comcould provide additional insights into reoccurring angina in
patients who undergo PCI.Acknowledgments
Special thanks are given to Po-Yung Cheng from CDC for
assistance with the statistical analyses. Appreciation is also given
to Jing Xu and Harinder Chahal for editing the manuscript.References
[1] Adams HPJr, del Zoppo G, Alberts MJ, et al. Guidelines for the early
management of adults with ischemic stroke: a guideline from the
American Heart Association/American Stroke Association Stroke
Council, Clinical Cardiology Council, Cardiovascular Radiology and
Intervention Council, and the Atherosclerotic Peripheral Vascular
Disease and Quality of Care Outcomes in Research Interdisciplinary
Working Groups: The American Academy of Neurology afﬁrms the
value of this guideline as an educational tool for neurologists. Circulation
2007;115:e478–534.
[2] Mathers CD, Loncar D. Projections of global mortality and burden of
disease from 2002 to 2030. PLoS Med 2006;3:e442.
[3] Santulli G. Coronary heart disease risk factors and mortality. JAMA
2012;307:1137author reply 1138.
[4] Santulli G, Trimarco B, Iaccarino G. G-protein-coupled receptor kinase 2
and hypertension: molecular insights and pathophysiological mecha-
nisms. High Blood Press Cardiovasc Prev 2013;20:5–12.
[5] Santulli G, Cipolletta E, Sorriento D, et al. CaMK4 Gene Deletion
Induces Hypertension. J Am Heart Assoc 2012;1:e001081.
[6] Lanni F, Santulli G, Izzo R, et al. The Pl(A1/A2) polymorphism of
glycoprotein IIIa and cerebrovascular events in hypertension: increased
risk of ischemic stroke in high-risk patients. J Hypertens 2007;25:
551–6.
[7] Galasso G, Santulli G, Piscione F, et al. The GPIIIA PlA2 polymorphism
is associated with an increased risk of cardiovascular adverse events.
BMC Cardiovasc Disord 2010;10:41.
[8] Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous
thrombolytic therapy for acute myocardial infarction: a quantitative
review of 23 randomised trials. Lancet 2003;361:13–20.
[9] Chang WC, Kaul P, Westerhout CM, et al. Impact of sex on long-term
mortality from acute myocardial infarction vs unstable angina. Arch
Intern Med 2003;163:2476–84.
[10] Hochman JS, Tamis JE, Thompson TD, et al. Sex, clinical presentation,
and outcome in patients with acute coronary syndromes. Global Use of
Strategies to Open Occluded Coronary Arteries in Acute Coronary
Syndromes IIb Investigators. N Engl J Med 1999;341:226–32.
[11] Tocci G, Barbato E, Coluccia R, et al. Blood pressure levels at the time of
percutaneous coronary revascularization and risk of coronary in-stent
restenosis. Am J Hypertens 2016;29:509–18.
[12] Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal
stenting in patients with diabetes mellitus: results from theMassachusetts
Data Analysis Center Registry. Circulation Nov 2008;118:2277–85.
2277p following 2285.
[13] Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart
disease in subjects with type 2 diabetes and in nondiabetic subjects with
and without prior myocardial infarction. N Engl J Med 1998;339:
229–34.
[14] Veltman CE, van der Hoeven BL, Hoogslag GE, et al. Inﬂuence of
coronary vessel dominance on short- and long-term outcome in patients
after ST-segment elevation myocardial infarction. Eur Heart J 2015;36:
1023–30.
[15] Veltman CE, de Graaf FR, Schuijf JD, et al. Prognostic value of coronary
vessel dominance in relation to signiﬁcant coronary artery disease
determined with non-invasive computed tomography coronary angiog-
raphy. Eur Heart J 2012;33:1367–77.
[16] Goldberg A, Southern DA, Galbraith PD, et al. Coronary dominance
and prognosis of patients with acute coronary syndrome. Am Heart J
2007;154:1116–22.
[17] Zhao FH, Chen YD, Song XT, et al. Predictive factors of recurrent angina
after acute coronary syndrome: the global registry acute coronary events
from China (Sino-GRACE). Chin Med J (Engl) 2008;121:12–6.
[18] Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in
patients with acute coronary syndromes undergoing invasive manage-
ment: a randomised multicentre trial. Lancet 2015;385:2465–76.7randomized investigation in ST-segment elevation acute coronary
syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized
Investigation in ST-Elevation Acute Coronary Syndrome) study. J Am
Coll Cardiol 2012;60:2481–9.
[20] Alexander KP, Cowper PA, Kempf JA, et al. Proﬁle of chronic and
recurrent angina pectoris in a referral population. Am J Cardiol
2008;102:1301–6.
[21] Venkitachalam L, Kip KE, Mulukutla SR, et al. Temporal Trends in
Patient-Reported Angina at 1 Year After Percutaneous Coronary
Revascularization in the Stent Era A Report From the National Heart,
Lung, and Blood Institute-Sponsored 1997-2006 Dynamic Registry.
Circ-Cardiovasc Qual 2009;2:607–15.
[22] Kini AS, Lee P, Mitre CA, et al. Postprocedure chest pain after coronary
stenting: Implications on clinical restenosis. J Am Coll Cardiol 2003;41:
33–8.
[23] Lemos PA, Hoye A, Serruys PW. Recurrent angina after revasculariza-
tion: an emerging problem for the clinician. Coronary Artery Dis 2004;
15:S11–5.
[24] Antman EM,HandM, Armstrong PW, et al. 2007 Focused Update of the
ACC/AHA 2004 Guidelines for the Management of Patients With ST-
Elevation Myocardial Infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guide-
lines: developed in collaboration With the Canadian Cardiovascular
Society endorsed by the American Academy of Family Physicians: 2007
Writing Group to Review New Evidence and Update the ACC/AHA
2004 Guidelines for the Management of Patients With ST-Elevation
Myocardial Infarction, Writing on Behalf of the 2004 Writing
Committee. Circulation 2008;117:296–329.
[25] McGillion M, Arthur HM, Natarajan M, et al. Nonischemic Chest Pain
Following Successful Percutaneous Coronary Intervention at a Regional
Referral Centre in Southern Ontario. Can J Cardiol 2012;28:S60–9.
[26] Spertus JA, Dawson J, Masoudi FA, et al. Prevalence and predictors of
angina pectoris one month after myocardial infarction. Am J Cardiol
2006;98:282–8.
[27] Song XT, Chen YD, Pan WQ, et al. Gender based differences in patients
with acute coronary syndrome: ﬁndings from Chinese Registry of Acute
Coronary Events (CRACE). Chin Med J (Engl) 2007;120:1063–7.
[28] Dougenis D, Kelly PJ, Brown AH. Late survival and predictors of
recurrent angina after coronary artery reoperation. Thorac Cardiovasc
Surg 1997;45:114–8.
[29] Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after
myocardial infarction: prevalence and associated ﬁndings. Arch Intern
Med 2008;168:1310–6.
[30] Stein B, Weintraub WS, Gebhart SP, et al. Inﬂuence of diabetes mellitus
on early and late outcome after percutaneous transluminal coronary
angioplasty. Circulation 1995;91:979–89.
[31] Elsman P, van’t Hof AW, de Boer MJ, et al. Impact of infarct location on
left ventricular ejection fraction after correction for enzymatic infarct size
in acute myocardial infarction treated with primary coronary interven-
tion. Am Heart J 2006;151:1239e1239-1214.
[32] Elsman P, van’t Hof AW, Hoorntje JC, et al. Effect of coronary occlusion
site on angiographic and clinical outcome in acute myocardial infarction
patients treated with early coronary intervention. Am J Cardiol
2006;97:1137–41.
[33] Stone GW, Peterson MA, Lansky AJ, et al. Impact of normalized
myocardial perfusion after successful angioplasty in acute myocardial
infarction. J Am Coll Cardiol 2002;39:591–7.
[34] Santulli G, Campanile A, Spinelli L, et al. G protein-coupled receptor
kinase 2 in patients with acute myocardial infarction. Am J Cardiol
2011;107:1125–30.
[35] Santulli G. Adrenal signaling in heart failure: something more than a
distant ship’s smoke on the horizon. Hypertension 2014;63:215–6.
[36] Tsunoda R, Sakamoto T, Kojima S, et al. Recurrence of angina pectoris
after percutaneous coronary intervention is reduced by statins in
Japanese patients. J Cardiol 2011;58:208–15.
[37] Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin
on early recurrent ischemic events in acute coronary syndromes: the
MIRACL study: a randomized controlled trial. JAMA 2001;285:
1711–8.
[38] Hamon M, Pristipino C, Di Mario C, et al. Consensus document on the
radial approach in percutaneous cardiovascular interventions: position
paper by the European Association of Percutaneous Cardiovascular
Interventions and Working Groups on Acute Cardiac Care∗∗ and
Thrombosis of the European Society of Cardiology. EuroIntervention
2013;8:1242–51.
[39] Jolly SS, Amlani S, Hamon M, et al. Radial versus femoral access for [42] Bernat I, Horak D, Stasek J, et al. ST-segment elevation myocardial
Zhang et al. Medicine (2016) 95:41 Medicinecoronary angiography or intervention and the impact on major bleeding
and ischemic events: a systematic review and meta-analysis of
randomized trials. Am Heart J 2009;157:132–40.
[40] Bertrand OF, Belisle P, Joyal D, et al. Comparison of transradial and
femoral approaches for percutaneous coronary interventions: a
systematic review and hierarchical Bayesian meta-analysis. Am Heart
J 2012;163:632–48.
[41] Agostoni P, Biondi-Zoccai GG, de Benedictis ML, et al. Radial versus
femoral approach for percutaneous coronary diagnostic and interven-
tional procedures; Systematic overview and meta-analysis of randomized
trials. J Am Coll Cardiol 2004;44:349–56.8infarction treated by radial or femoral approach in a multicenter
randomized clinical trial: the STEMI-RADIAL trial. J Am Coll Cardiol
2014;63:964–72.
[43] Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for
coronary angiography and intervention in patients with acute coronary
syndromes (RIVAL): a randomised, parallel group, multicentre trial.
Lancet 2011;377:1409–20.
[44] Karrowni W, Vyas A, Giacomino B, et al. Radial versus femoral access
for primary percutaneous interventions in ST-segment elevation
myocardial infarction patients: a meta-analysis of randomized controlled
trials. JACC Cardiovasc Interv 2013;6:814–23.
